Probability

Plug Power (PLUG) Sued by Investors For Concealing its 2023 Liquidity Problems - Hagens Berman

Retrieved on: 
Wednesday, March 27, 2024
Plug Power, SAN, Knowledge, News, Person, Alpha, Hydrogen, Hagens Berman, Probability, Cryptocurrency

SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Plug Power Inc. (NASDAQ: PLUG) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Plug Power Inc. (NASDAQ: PLUG) investors who suffered substantial losses to submit your losses now .
  • The firm also encourages persons with knowledge who may be able to assist in the investigation to contact the firm’s attorneys.
  • Plug Power Inc. (NASDAQ: PLUG) Securities Fraud Class Action:
    The litigation challenges Plug Power’s assurances that its buildout and construction of its green hydrogen production plants was “on track” and that it identified multiple non-dilutive opportunities to continue funding its operations.
  • “We are investigating whether Plug may have deceived investors about the sufficiency of its liquidity,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Retrieved on: 
Wednesday, March 27, 2024
Eli Lilly, Disease, Half-life, Partnership, Patient, Sale, Acquisition, Inflammation, Therapy, OrbiMed, Hidradenitis suppurativa, Probability, Autoimmune disease

Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027

Key Points: 
  • Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027
    Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T.
  • The private placement will provide up to $185 million in gross proceeds, including an initial gross upfront investment of $115.6 million.
  • After deducting estimated transaction costs from both the private placement financing and the acquisition of AlmataBio, Avalo expects net upfront proceeds to be approximately $105 million.
  • The private placement is expected to close on March 28, 2024, subject to the satisfaction of customary closing conditions.

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Administration, EGFR, Mutation, Index, Colorectal cancer, Cetuximab, Central nervous system, Novartis, Webcast, Patient, GBM, CNS, Neoplasm, Acquisition, G&A, Insurance, BRAF, NRAS, MEK, CRC, Melanoma, ASCO, ID, MTD, Research and development, Probability, Data, FDA, Outsourcing, FTD, Pharmaceutical industry

SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter and full year ended December 31, 2023.

Key Points: 
  • In addition, a strategic pipeline prioritization sharpened Erasca’s focus on existing programs that we believe have the highest probability of success for patients.
  • Research and Development (R&D) Expenses: R&D expenses were $24.8 million for the quarter ended December 31, 2023, compared to $29.4 million for the quarter ended December 31, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $9.1 million for the quarter ended December 31, 2023, compared to $8.7 million for the quarter ended December 31, 2022.
  • Erasca will hold a conference call and webcast on Thursday, March 28, 2024 at 8:30 am ET.

24-Provider Health Center Leverages eClinicalWorks and the healow No-Show Prediction AI Model to Enhance Access to Care

Retrieved on: 
Tuesday, April 9, 2024
Data Management, Health, Technology, Practice Management, Other Health, Software, Artificial Intelligence, FQHC, Inc., Risk, Education, Patient, AI, Statistics, EHR, Machine learning, Probability, Nursing

HealthCare Choices NY, Inc. – a federally qualified health center (FQHC), is successfully leveraging the healow ® no-show prediction AI model and eClinicalWorks EHR to reduce the no-show rate, increase revenue outcomes and ultimately improve patient care.

Key Points: 
  • HealthCare Choices NY, Inc. – a federally qualified health center (FQHC), is successfully leveraging the healow ® no-show prediction AI model and eClinicalWorks EHR to reduce the no-show rate, increase revenue outcomes and ultimately improve patient care.
  • The community health center successfully increased the show rate for appointments with a high no-show rate by 155%.
  • The practice strives to strengthen the community’s health by providing open access to supportive services, including testing, prevention, referral to care, and education.
  • By leveraging the healow no-show prediction AI model , the practice efficiently identifies which appointments will likely be missed, enabling the community center to better manage its scheduling strategy.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Plug Power Inc. (PLUG)

Retrieved on: 
Tuesday, April 9, 2024
Class Action Lawsuit, Professional Services, Legal, Law, Telephone, Defendant, News, Alpha, Plug, Suite, Hydrogen, GAAP, Probability, Court, Cryptocurrency

Law Offices of Howard G. Smith reminds investors of the upcoming May 21, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Plug Power Inc. (“Plug” or the “Company”) (NASDAQ: PLUG ) securities between May 9, 2023 and January 16, 2024, inclusive (the “Class Period”).

Key Points: 
  • Law Offices of Howard G. Smith reminds investors of the upcoming May 21, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Plug Power Inc. (“Plug” or the “Company”) (NASDAQ: PLUG ) securities between May 9, 2023 and January 16, 2024, inclusive (the “Class Period”).
  • Investors suffering losses on their Plug investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at (215) 638-4847 or by email to [email protected] .
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Depression, Eli Lilly, Major depressive disorder, Patient, Bristol Myers Squibb, PureTech Health, PRTC, Therapy, Creativity, Disorder, General counsel, CNS, Life, DSM-IV codes, Pleasure, Pharmacokinetics, Interim, Third Rock Ventures, U.S. FDA, Schizophrenia, KarXT, Teva Pharmaceuticals, ARCH Venture Partners, Merck, Anxiety, Merck & Co., Research and development, FDA, Lymphatic system, Hepatotoxicity, Sirna Therapeutics, Generalized anxiety disorder, Growth, Neuropsychiatry, Partner, Multimedia, Eli Lilly and Company, Probability, Liver, Medicine, Pharmaceutical industry

Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.

Key Points: 
  • Following the Series A financing, PureTech will hold equity ownership in Seaport of 61.5 percent on a diluted basis.
  • Under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.
  • Eric Elenko, Ph.D., a PureTech co-founder and current Chief Innovation Officer, has been promoted to the role of President of PureTech.
  • Daphne Zohar, the Chief Executive Officer of Seaport, is the founder and former CEO of PureTech Health where she also co-founded Karuna Therapeutics.

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, Neurology, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Depression, Eli Lilly, U.S. FDA, Schizophrenia, KarXT, Major depressive disorder, ARCH Venture Partners, Patient, CNS, Anxiety, Bristol Myers Squibb, PureTech Health, DSM-IV codes, Pleasure, Neuropsychiatry, Research and development, Therapy, Pharmacokinetics, Partner, Disorder, Third Rock Ventures, Probability, FDA, Lymphatic system, Hepatotoxicity, Liver, Medicine, Pharmaceutical industry

Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.

Key Points: 
  • Seaport Therapeutics , a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million oversubscribed Series A financing round.
  • The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health.
  • Seaport is advancing a clinical-stage pipeline of novel neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms.
  • I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.”

Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Two Patient Cohorts

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Pharmaceutical, Managed Care, Oncology, General Health, Health, FDA, Clinical Trials, NMIBC, BCG, Toxicity, HG, Physician, Congress, Nadofaragene firadenovec, Survival, PD, Cystectomy, Ferring Pharmaceuticals, Patient, Aes, EAU, MD Anderson Cancer Center, University, Month, Carcinoma in situ, Safety, Division, Probability, CIS, Food, Pharmaceutical industry

“Intravesical gene therapy represents an important innovative treatment option for these patients.

Key Points: 
  • “Intravesical gene therapy represents an important innovative treatment option for these patients.
  • The efficacy analysis included 103 and 48 patients in the CIS and PD cohorts, respectively, who met the protocol definition of BCG-unresponsive NMIBC.
  • In total, 12.1% (13/107) and 20.0% (10/50) of patients in the CIS and PD cohorts, respectively, received ADSTILADRIN at three years.
  • In the CIS cohort, about 53% achieved a complete response (CR) at Month 3 in the primary analysis.

From Miles Above, Satellite Data Helps Spot Hazardous Trees and Reduce Wildfire Risk

Retrieved on: 
Monday, April 8, 2024
PG&E, Intelligence, Partnership, Risk, Wildfire, The Electric Company, Tree, Probability, Vegetation, Silviculture

OAKLAND, Calif., April 8, 2024 /PRNewswire/ -- Preventing ignitions that can cause catastrophic wildfires requires focus, vigilance and the integration of ever-evolving technology. And as Pacific Gas and Electric Company (PG&E) continues to make progress – including what the Company has calculated to be a 72% reduction of ignitions in high fire-risk areas in 2023 compared to the three-year average – satellite technology plays an increasing role.

Key Points: 
  • One example is PG&E's partnership with Planet Labs PBC (NYSE: PL), a San Francisco-based provider of daily data and insights about Earth.
  • PG&E leverages Planet's satellite-derived data on vegetation including canopy height, cover and proximity to electric-system infrastructure to prioritize the mitigation of vegetation associated risks.
  • Since 2019, PG&E has used data from Salo Sciences, acquired by Planet in 2023, as a feeder data set into its wildfire risk models.
  • "Planet's satellite data and artificial intelligence supports broad area management to help reduce the risk of wildfires.

Americans Actually Agree On A Lot, Per New National Survey

Retrieved on: 
Monday, April 8, 2024
Temperature, Connection, Len Bias, The Harris Poll, Education, Social media, Research, News, Food, Reveal, Behavior, HERE, Love, Negativity, Probability, Marital status

SHEBOYGAN FALLS, Wis., April 8, 2024 /PRNewswire/ -- Johnsonville, the No. 1 national sausage brand, knows a thing or two about links. In a new poll released today, the company reveals what links Americans. Johnsonville's National Temperature Check is a new national survey of 2,060 U.S. adults conducted online by The Harris Poll from Feb. 29 - March 4.

Key Points: 
  • Johnsonville's National Temperature Check is a new national survey of 2,060 U.S. adults conducted online by The Harris Poll from Feb. 29 - March 4.
  • The data shows Americans are finding it harder to have fun with people, and generally hanging out together less.
  • Other key findings from Johnsonville's National Temperature Check survey include:
    It should come as no surprise, but Americans are exhausted, especially by what they see in the media.
  • Johnsonville's National Temperature Check found that 80% of adult Americans expressed they are exhausted by the anger and negativity in America.